カテゴリ： Allied Market Research, 世界, 医療/バイオ

出血性疾患のグローバル市場（2023-2032）：血友病A、血友病B、フォンヴィレブランド病、その他

■ 英語タイトル：Bleeding Disorders Market By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type (Factor Replacement Therapy, Drug Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP133）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP133
■ 発行日：2023年5月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：458
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[出血性疾患のグローバル市場（2023-2032）：血友病A、血友病B、フォンヴィレブランド病、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

出血性疾患市場は、2022年には137億8,966万ドルと評価され、2023年から2032年までの年平均成長率は6.6%で、2032年には259億7,482万ドルに達すると予測されています。 出血性疾患は、血液中の特定の凝固因子の欠乏または機能不全による異常出血を特徴とする疾患群です。通常、人が怪我をしたり切り傷を負ったりすると、身体は血栓を形成して出血を止めます。しかし、出血性疾患の患者さんでは、このプロセスが損なわれているか、欠如しているため、異常出血や過剰出血を起こすことがあります。血友病は最もよく知られた一般的な出血性疾患で、主に男性が罹患し、生命を脅かす重篤な出血エピソードを引き起こすことがあります。フォン・ヴィレブランド病も一般的な出血性疾患で、男女ともに罹患し、怪我や手術後に出血が長引くことがあります。

出血性疾患市場の成長を促進する主な要因としては、出血性疾患の治療における急速な進歩、血友病A、血友病B、その他の出血性疾患に罹患する患者数の増加などが挙げられます。例えば、米国疾病予防管理センター（CDC）2022によると、米国では男性33,000人が出血性疾患を患っています。

さらに、血友病管理に対する政府の積極的な取り組み、出血性疾患治療に関する啓発プログラムの増加、抗血友病薬開発のための臨床試験数の増加が出血性疾患市場の成長を後押ししています。さらに、対象人口の増加、診断率の上昇、血友病の予防的治療の急増が市場の成長を促進します。
しかし、血友病治療の高額な費用や血漿由来製品に関連する重篤な副作用が、出血性疾患市場の成長を制限すると予想されます。それとは逆に、医療費の急増や、発展途上国における血友病に対するより良い治療選択肢を得るための満たされていない医療需要は、将来的に世界市場拡大のための絶大な機会を生み出すと期待されています。

出血性疾患市場は、疾患タイプ、治療タイプ、流通チャネル、地域によって区分されます。疾患タイプ別では、市場は血友病A、血友病B、フォンウィルブランド病、その他に分類されます。治療タイプ別では、市場は因子補充療法、薬物療法（デスモプレシン、抗線溶薬、フィブリンシーラント）に分類されます。因子補充療法分野はさらに、血漿由来凝固因子濃縮製剤と遺伝子組換え凝固因子濃縮製剤に二分されます。流通チャネル別では、出血性疾患市場は病院薬局、ドラッグストアおよび小売薬局、オンライン薬局に区分されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋地域（中国、日本、オーストラリア、インド、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）で市場を分析します。

本レポートに掲載されている主な企業は、Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limitedです。市場の主要企業は、出血性疾患市場の製品ポートフォリオを改善するための主要な開発戦略として、投資、提携、製品承認を採用しています。

ステークホルダーにとっての主な利点
本レポートは、2022年から2032年までの出血性疾患市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、一般的な出血性疾患市場の機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
出血性疾患市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
出血性疾患の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
疾患タイプ別
血友病A
血友病B
フォンウィルブランド病
その他

治療タイプ別
因子補充療法
種類
遺伝子組換え凝固因子製剤
血漿由来凝固因子製剤
薬物療法

販売チャネル別
病院薬局
ドラッグストア・小売薬局
オンライン薬局

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Medexus Pharma, Inc.
○ Bayer AG
○ Novo Nordisk A/S
○ Grifols, S.A.
○ Octapharma AG
○ Takeda Pharmaceutical Company Limited
○ CSL Limited
○ Pfizer Inc.
○ Sanofi
○ F. Hoffmann-La Roche Ltd.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：出血性疾患市場、疾患タイプ別
第5章：出血性疾患市場、治療タイプ別
第6章：出血性疾患市場、流通チャネル別
第7章：出血性疾患市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of hemophilia
3.4.1.2. Technological advancements in treatment of hemophilia
3.4.1.3. Favorable government initiatives for hemophilia management

3.4.2. Restraints
3.4.2.1. High cost of bleeding disorders treatments

3.4.3. Opportunities
3.4.3.1. Rise in awareness about bleeding disorders in developing countries

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hemophilia A
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hemophilia B
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Von Willebrand Disease
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Factor Replacement Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
5.3. Drug Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Disease Type
7.2.3. Market size and forecast, by Treatment Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Disease Type
7.2.5.1.3. Market size and forecast, by Treatment Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Disease Type
7.2.5.2.3. Market size and forecast, by Treatment Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Disease Type
7.2.5.3.3. Market size and forecast, by Treatment Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Disease Type
7.3.3. Market size and forecast, by Treatment Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Disease Type
7.3.5.1.3. Market size and forecast, by Treatment Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Disease Type
7.3.5.2.3. Market size and forecast, by Treatment Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Disease Type
7.3.5.3.3. Market size and forecast, by Treatment Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Disease Type
7.3.5.4.3. Market size and forecast, by Treatment Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Disease Type
7.3.5.5.3. Market size and forecast, by Treatment Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Disease Type
7.3.5.6.3. Market size and forecast, by Treatment Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Disease Type
7.4.3. Market size and forecast, by Treatment Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Disease Type
7.4.5.1.3. Market size and forecast, by Treatment Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Disease Type
7.4.5.2.3. Market size and forecast, by Treatment Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Disease Type
7.4.5.3.3. Market size and forecast, by Treatment Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Disease Type
7.4.5.4.3. Market size and forecast, by Treatment Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Disease Type
7.4.5.5.3. Market size and forecast, by Treatment Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Disease Type
7.4.5.6.3. Market size and forecast, by Treatment Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Disease Type
7.5.3. Market size and forecast, by Treatment Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Disease Type
7.5.5.1.3. Market size and forecast, by Treatment Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Disease Type
7.5.5.2.3. Market size and forecast, by Treatment Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Disease Type
7.5.5.3.3. Market size and forecast, by Treatment Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Disease Type
7.5.5.4.3. Market size and forecast, by Treatment Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Novo Nordisk A/S
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Bayer AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Octapharma AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Medexus Pharma, Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Grifols, S.A.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. CSL Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Takeda Pharmaceutical Company Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 02. BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY REGION, 2022-2032 ($MILLION)
TABLE 04. BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 05. BLEEDING DISORDERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 07. BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL FACTOR REPLACEMENT THERAPY BLEEDING DISORDERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 09. BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. BLEEDING DISORDERS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 20. U.S. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. CANADA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 23. CANADA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. MEXICO BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 26. MEXICO BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 29. EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 33. GERMANY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. FRANCE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 36. FRANCE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. UK BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 39. UK BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. ITALY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 42. ITALY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. SPAIN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 45. SPAIN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 55. JAPAN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. CHINA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 58. CHINA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. INDIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 64. INDIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. INDIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 73. LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 77. BRAZIL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. PFIZER INC.: KEY EXECUTIVES
TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 92. PFIZER INC.: KEY STRATERGIES
TABLE 93. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 94. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 95. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 96. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 97. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 98. BAYER AG: KEY EXECUTIVES
TABLE 99. BAYER AG: COMPANY SNAPSHOT
TABLE 100. BAYER AG: PRODUCT SEGMENTS
TABLE 101. BAYER AG: PRODUCT PORTFOLIO
TABLE 102. OCTAPHARMA AG: KEY EXECUTIVES
TABLE 103. OCTAPHARMA AG: COMPANY SNAPSHOT
TABLE 104. OCTAPHARMA AG: PRODUCT SEGMENTS
TABLE 105. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 106. OCTAPHARMA AG: KEY STRATERGIES
TABLE 107. SANOFI: KEY EXECUTIVES
TABLE 108. SANOFI: COMPANY SNAPSHOT
TABLE 109. SANOFI: PRODUCT SEGMENTS
TABLE 110. SANOFI: PRODUCT PORTFOLIO
TABLE 111. SANOFI: KEY STRATERGIES
TABLE 112. MEDEXUS PHARMA, INC.: KEY EXECUTIVES
TABLE 113. MEDEXUS PHARMA, INC.: COMPANY SNAPSHOT
TABLE 114. MEDEXUS PHARMA, INC.: PRODUCT SEGMENTS
TABLE 115. MEDEXUS PHARMA, INC.: PRODUCT PORTFOLIO
TABLE 116. MEDEXUS PHARMA, INC.: KEY STRATERGIES
TABLE 117. GRIFOLS, S.A.: KEY EXECUTIVES
TABLE 118. GRIFOLS, S.A.: COMPANY SNAPSHOT
TABLE 119. GRIFOLS, S.A.: PRODUCT SEGMENTS
TABLE 120. GRIFOLS, S.A.: PRODUCT PORTFOLIO
TABLE 121. GRIFOLS, S.A.: KEY STRATERGIES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 127. CSL LIMITED: KEY EXECUTIVES
TABLE 128. CSL LIMITED: COMPANY SNAPSHOT
TABLE 129. CSL LIMITED: PRODUCT SEGMENTS
TABLE 130. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 131. CSL LIMITED: KEY STRATERGIES
TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 134. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 135. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 136. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 出血性疾患治療のグローバル市場（2022年-2029年）：血友病A、血友病B、フォン・ヴィレブランド病、その他
  • 出血性疾患治療のグローバル市場：血友病A、血友病B、フォンウィルブランド病、その他
  • 血液疾患のグローバル市場（～2030年）： 血友病A、血友病B、フォンウィルブランド病、その他
  • 血友病のグローバル市場：血友病A、血友病B、血友病C、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP133 )"出血性疾患のグローバル市場（2023-2032）：血友病A、血友病B、フォンヴィレブランド病、その他" (英文：Bleeding Disorders Market By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type (Factor Replacement Therapy, Drug Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。